Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Subcutaneous Route and Pharmacology of Metoclopramide
NCT02466984Phase 3Completed
- Sponsor
- Centre Hospitalier Universitaire de Bordeaux
- Start
- Jul 2016
- Primary completion
- Feb 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of metoclopramide in nausea ((none)) and Vomiting (2 arms), sponsored by Centre Hospitalier Universitaire de Bordeaux. Primary endpoint: Absolute bioavailability of SubCutaneus administration metoclopramide at 13 days. Started Jul 2016; status: completed.
02
Drugs
metoclopramide
03
Conditions
nausea ((none))Vomiting
Beyond the preview
Go deeper on NCT02466984.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02466984.